Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-05-11
Based on 1098 first isolates · ED · Cystitis (lower UTI) · 2024-05-12 → 2025-05-11
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (82 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
84 %
n = 93
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
85 %
n = 93
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
77 %
n = 93
ciprofloxacin CIP
trend · Escherichia coli
79 %
78 %
n = 93
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
74 %
n = 93
ceftriaxone CRO
trend · Escherichia coli
77 %
69 %
n = 93
trimethoprim TMP
trend · Escherichia coli lower UTI only
73 %
66 %
n = 93
73 %
63 %
n = 93
53 %
51 %
n = 93
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
14 %
n = 93
5 %
10 %
n = 93
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 93

Most likely organisms for this profile

Escherichia coli
55 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.